BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

@article{Ku2014BYL719AS,
  title={BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer},
  author={Bo Mi Ku and Eun Hye Jho and Yeon-Hee Bae and Jong-mu Sun and Jin Seok Ahn and Keunchil Park and Myung-ju Ahn},
  journal={Investigational New Drugs},
  year={2014},
  volume={33},
  pages={12-21}
}
Purpose KRAS is frequently mutated in non-small cell lung cancers (NSCLC), resulting in activation of the MEK/ERK pathway. Because there are currently no drugs that target oncogenic KRAS, MEK inhibitors have been tested clinically as a possible treatment option for patients with NSCLC. However, KRAS-mutant cancers exhibit resistance to MEK inhibitors. Therefore, a combinational strategy is necessary for effective therapy. To address this, we investigated the therapeutic effects of combining… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

: a meta - analysis of 22 studies

  • PA Janne, AT Shaw, +9 authors L Crino
  • 2013

Similar Papers

Loading similar papers…